Table 2.

Literature review: patients with the SLE/AAV overlap syndrome from previous reports

Number	Author	Time (yr)	Gender	Age	Associated autoimmune disease	First disease and age at diagnosis (yr)	Second disease and age at diagnosis (yr)	MPO-ANCA	PR3-ANCA	SLEDAI	LowC3/C4	Treatment	Outcome	Renal clinical and biological involvement
1[8,9]	Motohide Isono	2011	F	74	Selective IgM deficiency	SLE, 74	MPA, 74	+	−		C3:0. 39 mg/mL C4:0. 01 mg/mL	CS + PE	Died	Serum creatinine 2.6 mg/dL
2[10]	Shoko Kobayashi	2009	F	42	–	SLE, 37	MPA, 42	+	−	4		CS	Remission	Hematuria or albuminuria
				48		SLE, 37	MPA, 42	−	−	8		CS	Died
3[11]	Pierre-Andre Jarrot	2016	F	57	–	SLE, 38	AAV, 55	+	−	16	−/−	CS, CYC, HCQ	Remission	RPGN hematuria/leucocyturia
4[11]	Pierre-Andre Jarrot	2016	F	29	Graves–Basedow disease	AAV, 12	SLE, 17	+	−	17	−/−	CS, CYC	Remission	Proteinuria hematuria/leucocyturia
5[11]	Pierre-Andre Jarrot	2016	F	74	Idiopathic thrombopenic purpura	SLE, 74	AAV, 74	+	−	26	−/−	PE, CS, CYC, MMF	Died	RPGN hematuria/leucocyturia

AAV = ANCA-associated vasculitis, ANCA = anti-neutrophil cytoplasmic antibody, CS = corticosteroids, CYC = cyclophosphamide, HCQ = hydroxychloroquine, MMF = mycophenolate mofetil, MPO = myeloperoxidase, PE = plasma exchange, RPGN = rapid progressive glomerulonephritis, SLE = systemic lupus erythematosus, SLEDAI = SLE disease activity index.